New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDulaglutide vs PE-22-28

Dulaglutide vs PE-22-28

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Dulaglutide
Cognitive Enhancement
PE-22-28
Summary
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
Half-Life
~5 days
Relatively short; CNS effects may persist due to neurogenic mechanisms
Admin Route
SubQ
SubQ, Intranasal
Research
Typical Dose
0.75 mg → 1.5 mg
200–400 mcg
Frequency
Once weekly
Once daily
Key Benefits
  • FDA-approved for type 2 diabetes
  • Once-weekly subcutaneous dosing via auto-injector pen
  • Reduces HbA1c by approximately 1.1–1.6%
  • Modest weight loss of 1.5–3 kg at approved doses
  • Demonstrated cardiovascular risk reduction (REWIND trial)
  • Established long-term safety profile
  • Renal protective effects in CKD
  • Rapid-onset antidepressant effects (within 24 hours)
  • Promotes hippocampal neurogenesis
  • Improves cognitive performance and memory
  • Reduces anxiety and depressive behavior
  • Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
  • May help treatment-resistant depression
  • Neuroprotective effects
Side Effects
  • Nausea (most common, typically transient)
  • Diarrhea
  • Vomiting
  • Decreased appetite
  • +3 more
  • Generally well tolerated in animal models
  • Limited human data available
  • Possible mild headache or transient mood changes at initiation
  • Injection site reactions (SC)
Stacks With